Nature:突破!单克隆抗体或有望治疗冠心病!

2018-06-10 Michael,Zoe 转化医学网

加利福尼亚大学圣地亚哥分校医学院的研究人员发现,抗氧化磷脂(OxPL)抗体通过与细胞表的氧化磷脂(OxPL)结合,不仅可以阻断小鼠体内的炎症反应, 即使在高脂饮食中,抗体还能保护小鼠免受动脉斑块形成,动脉硬化和肝脏疾病的侵袭,并延长其寿命。这篇文章发表于近日的《Nature》杂志。

导  读


加利福尼亚大学圣地亚哥分校医学院的研究人员发现,抗氧化磷脂(OxPL)抗体通过与细胞表的氧化磷脂(OxPL)结合,不仅可以阻断小鼠体内的炎症反应, 即使在高脂饮食中,抗体还能保护小鼠免受动脉斑块形成,动脉硬化和肝脏疾病的侵袭,并延长其寿命。这篇文章发表于近日的《Nature》杂志。

动脉粥样硬化是心肌梗死和脑梗死的核心发生机制。科研人员对其的研究已经持续数十年。其演变学说以当前的脂质侵润学说认可度最广。

动脉粥样硬化如何形成的?

当人或动物在高脂饮食等应激刺激下,大量脂质沉积于血管的内皮下层,这其中大部分脂质为低密度脂蛋白(LDL)。这些低密度脂蛋白就是心肌梗死和脑梗死的罪魁祸首!市面上用于降低血脂的他汀类药物实质主要是降低血液当中的低密度脂蛋白。

目前最新的临床指南指出,动脉粥样硬化患者的低密度脂蛋白水平应该降低至1.8mmol/L以下或者降低至之下的50%以下,这充分说明了低密度脂蛋白在动脉粥样硬化进展的关键作用!

氧化磷脂与抗氧化磷脂抗体

氧化磷脂(OxPL)表达在低密度脂蛋白、凋亡的细胞表面以及泡沫细胞分泌的大量细胞因子表面,同时能够介导巨噬细胞和血管平滑肌细胞对低密度脂蛋的识别。简单点说,如果能够减少氧化磷脂,就可以降低低密度脂蛋白的有害作用。

研究人员提取的抗氧化磷脂抗体能够识别氧化低密度脂蛋白、凋亡细胞表面的氧化磷脂,但并不能识别磷脂的非氧化型。在此后的研究中,科研人员发现抗氧化磷脂抗体能够阻断巨噬细胞对于氧化低密度脂蛋白(Ox-LDL)的识别,降低血管内皮的炎性反应。

抗Ox-PL抗体与转基因小鼠

为了研究氧化磷脂与动脉粥样硬化的分子生物学机制,科研人员利用转基因技术将抗氧化磷脂抗体(E06)的基因转入小鼠体内,构建了一种体内血浆表达高浓度抗氧化磷脂抗体的小鼠模型。

通过给与这些转基因小鼠和普通小鼠高脂饮食,研究人员试图发现氧化磷脂与动脉粥样硬化之间的关系。结果显示,与对照组相比,能够表达抗氧化磷脂抗体的小鼠罹患动脉粥样硬化的概率低28%-57%。同时该抗体能够明显减少瓣膜钙化、脂肪肝和肝脏炎症的发生。

目前Wiztum与其团队正在通过该小鼠模型测试抗磷脂抗体与炎症相关的其他人类疾病,如骨质疏松和非酒精性肝炎中的作用。相信在不远的未来,单克隆抗体能够被用于治疗众多人类疾病。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1660168, encodeId=cd281660168ba, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed May 22 04:20:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883087, encodeId=506e188308e39, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 04 20:20:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324364, encodeId=2c0d32436453, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Jun 15 08:42:30 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323233, encodeId=a6de32323331, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Jun 11 07:15:17 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323121, encodeId=9d64323121c6, content=冠心病治疗新突破.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Jun 10 21:46:22 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323106, encodeId=64b932310685, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Jun 10 20:19:42 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323083, encodeId=a46d323083ba, content=值得期待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Jun 10 17:59:53 CST 2018, time=2018-06-10, status=1, ipAttribution=)]
    2019-05-22 aids221
  2. [GetPortalCommentsPageByObjectIdResponse(id=1660168, encodeId=cd281660168ba, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed May 22 04:20:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883087, encodeId=506e188308e39, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 04 20:20:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324364, encodeId=2c0d32436453, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Jun 15 08:42:30 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323233, encodeId=a6de32323331, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Jun 11 07:15:17 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323121, encodeId=9d64323121c6, content=冠心病治疗新突破.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Jun 10 21:46:22 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323106, encodeId=64b932310685, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Jun 10 20:19:42 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323083, encodeId=a46d323083ba, content=值得期待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Jun 10 17:59:53 CST 2018, time=2018-06-10, status=1, ipAttribution=)]
    2018-10-04 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1660168, encodeId=cd281660168ba, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed May 22 04:20:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883087, encodeId=506e188308e39, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 04 20:20:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324364, encodeId=2c0d32436453, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Jun 15 08:42:30 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323233, encodeId=a6de32323331, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Jun 11 07:15:17 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323121, encodeId=9d64323121c6, content=冠心病治疗新突破.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Jun 10 21:46:22 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323106, encodeId=64b932310685, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Jun 10 20:19:42 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323083, encodeId=a46d323083ba, content=值得期待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Jun 10 17:59:53 CST 2018, time=2018-06-10, status=1, ipAttribution=)]
    2018-06-15 一天没事干

    很好的学习机会

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1660168, encodeId=cd281660168ba, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed May 22 04:20:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883087, encodeId=506e188308e39, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 04 20:20:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324364, encodeId=2c0d32436453, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Jun 15 08:42:30 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323233, encodeId=a6de32323331, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Jun 11 07:15:17 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323121, encodeId=9d64323121c6, content=冠心病治疗新突破.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Jun 10 21:46:22 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323106, encodeId=64b932310685, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Jun 10 20:19:42 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323083, encodeId=a46d323083ba, content=值得期待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Jun 10 17:59:53 CST 2018, time=2018-06-10, status=1, ipAttribution=)]
    2018-06-11 kafei

    学习了谢谢

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1660168, encodeId=cd281660168ba, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed May 22 04:20:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883087, encodeId=506e188308e39, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 04 20:20:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324364, encodeId=2c0d32436453, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Jun 15 08:42:30 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323233, encodeId=a6de32323331, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Jun 11 07:15:17 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323121, encodeId=9d64323121c6, content=冠心病治疗新突破.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Jun 10 21:46:22 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323106, encodeId=64b932310685, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Jun 10 20:19:42 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323083, encodeId=a46d323083ba, content=值得期待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Jun 10 17:59:53 CST 2018, time=2018-06-10, status=1, ipAttribution=)]
    2018-06-10 1e0f8808m18(暂无匿称)

    冠心病治疗新突破.学习了.

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1660168, encodeId=cd281660168ba, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed May 22 04:20:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883087, encodeId=506e188308e39, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 04 20:20:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324364, encodeId=2c0d32436453, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Jun 15 08:42:30 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323233, encodeId=a6de32323331, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Jun 11 07:15:17 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323121, encodeId=9d64323121c6, content=冠心病治疗新突破.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Jun 10 21:46:22 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323106, encodeId=64b932310685, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Jun 10 20:19:42 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323083, encodeId=a46d323083ba, content=值得期待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Jun 10 17:59:53 CST 2018, time=2018-06-10, status=1, ipAttribution=)]
    2018-06-10 天地飞扬

    了解一下.谢谢分享!

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1660168, encodeId=cd281660168ba, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed May 22 04:20:00 CST 2019, time=2019-05-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1883087, encodeId=506e188308e39, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Oct 04 20:20:00 CST 2018, time=2018-10-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=324364, encodeId=2c0d32436453, content=很好的学习机会, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/04/12/cd30eefc465f70dc4dad89bd57479781.jpg, createdBy=02be2318568, createdName=一天没事干, createdTime=Fri Jun 15 08:42:30 CST 2018, time=2018-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323233, encodeId=a6de32323331, content=学习了谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTLbTp9nZtjwVrSZNxAXbAicnKQWnic2eBdJUQYhxO36XdkstSicr7FVF8p5ReH4omtmsbnLdvZLiaJJ1A/132, createdBy=8bff2327056, createdName=kafei, createdTime=Mon Jun 11 07:15:17 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323121, encodeId=9d64323121c6, content=冠心病治疗新突破.学习了., beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sun Jun 10 21:46:22 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323106, encodeId=64b932310685, content=了解一下.谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Sun Jun 10 20:19:42 CST 2018, time=2018-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=323083, encodeId=a46d323083ba, content=值得期待啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKibA62IFMeUJEmSyIe8DvYFeERuOsfrRd8iano7nENqQU1dRR3tqeQOUL3eqgYgEZRT2t2iaEsib0JEw/132, createdBy=66771693911, createdName=易水河, createdTime=Sun Jun 10 17:59:53 CST 2018, time=2018-06-10, status=1, ipAttribution=)]
    2018-06-10 易水河

    值得期待啊

    0

相关资讯

Leukemia:复发/难治性MM治疗进展:新药、单克隆抗体及免疫治疗

近年,尽管随着蛋白酶体抑制剂(PIs)、免疫调节剂(IMiDs)等新药的出现,多发性骨髓瘤(MM)的疗效及预后获得了显著的改善,但绝大部分MM患者仍最终出现疾病复发及进展。总体而言,复发/难治多发性骨髓瘤(RRMM)仍是治疗上的难点,因此也是当前临床研究的热点方向。那么,如何全面快速地Get到RRMM的最新治疗进展呢?CS Chim教授等在Leukemia杂志上发表了一篇关于RRMM研究进展的综述

Cell Rep:抗寨卡病毒人源单克隆抗体研究获进展

寨卡病毒是以埃及伊蚊等为媒介传播的黄热病毒,也可通过血液、母婴和性接触传播。寨卡病毒感染导致新生儿小颅畸形症以及格林-巴利综合症等严重神经系统疾病受到了国际上的密切关注,世界卫生组织将此次寨卡疫情宣布为“国际关注的突发公共卫生事件”。截至目前,临床上仍没有针对寨卡病毒的特异性治疗药物和预防性疫苗正式上市。中国科学院遗传与发育生物学研究所研究员许执恒、清华大学医学院教授张林琦和广州市第八人民医院教授

Mol Ther:上海药物所发现整合素aIIbβ3的种属差异与单抗诱导的血小板减少症相关

在目前世界范围内,治疗性单克隆抗体(Monoclonal antibodies,mAbs)销售额已达数百亿美元,占到整个生物制药市场份额的三成以上。虽然大部分mAbs在人体中能够良好地耐受,但也依然会造成包括免疫反应、感染性疾病、自身免疫疾病、血小板减少、血栓形成障碍、皮炎及心血管毒性等毒副作用。因此,如何在药物研发前期尽早地发现mAbs造成的不良反应显得极为重要。

罗氏旗下奥美珠单抗经欧盟批准用于复发性及进展性多发性硬化症的治疗

罗氏公司的多发性硬化症(MS)治疗药物Ocrevus(奥美珠单抗)自上市以来在美国市场上获得了强劲的发展,在上市后的前六个月内销售额就已经超过了5亿美元;在原发性进行性MS患者中的使用率约为40%,在复发性MS患者中的使用率约为60%,并且在广泛的口服型和注射型竞争品中均表现优异,其长效特征(6个月输液一次,每年只需输液2次)更有望显著改善MS患者的依从性。

Cancer Cell:淋巴瘤免疫治疗新策略

英国南安普敦大学医学院血液肿瘤系Sean Hua Lim 团队检测了anti-CD20单克隆抗体与一系列免疫调节单克隆抗体的协同作用后的治疗潜力,发现只有anti-CD27/CD20的综合治疗能得到治愈的效果,其在淋巴瘤模型里尤其明显,包括使用huCD27转基因小鼠。使用单细胞RNA测序发现anti-CD27刺激CD8+T细胞和自然杀伤性细胞来释放髓样趋化因子以及干扰素γ,进而诱发髓细胞浸润以及巨

2018 ASCO:“治愈”卡特总统的恶性黑色素瘤免疫治疗新进展

黑色素瘤以发病率低、死亡率高、治疗难度大而被称之为“癌中之王”,而晚期黑色素瘤更被称为是“不能治疗”疾病。世界范围内恶性黑色素瘤发病率呈逐年上升的趋势,而近几十年来,以化疗为主的标准治疗对这类疾病却捉襟见肘。